Do Not Prescribe Azithromycin (Z-Pak) for Acute Cough Starting Today
For a patient with an acute cough that began today, prescribing azithromycin is inappropriate and should be declined. More than 90% of acute cough presentations in otherwise healthy adults are viral in origin, and antibiotics provide no benefit while exposing patients to unnecessary adverse effects 1.
Why Antibiotics Are Not Indicated
The Evidence Against Routine Antibiotic Use
The 2016 ACP/CDC guidelines explicitly recommend against routine antibiotic treatment for acute bronchitis in the absence of pneumonia 1. This recommendation is based on:
- Systematic review of 15 randomized controlled trials showing limited evidence supporting antibiotics with a trend toward increased adverse events 1
- A randomized placebo-controlled trial demonstrating no significant difference in days to cough resolution between antibiotics and placebo 1
- Azithromycin specifically was associated with significantly more adverse events than placebo in patients with acute bronchitis 1
The 2020 CHEST Expert Panel reinforced this, recommending no routine prescription of antibiotic therapy for immunocompetent adults with acute bronchitis 2.
Distinguishing Viral from Bacterial Infection
Key clinical point: Purulent (green or yellow) sputum does NOT indicate bacterial infection—it reflects inflammatory cells and sloughed epithelial cells, not bacteria 1.
For a cough starting today, you must first rule out pneumonia. Pneumonia is unlikely in healthy immunocompetent adults under 70 years without ALL of the following 1:
- Tachycardia (heart rate >100 bpm)
- Tachypnea (respiratory rate >24 breaths/min)
- Fever (oral temperature >38°C)
- Abnormal chest examination findings (rales, egophony, tactile fremitus)
If these criteria are not met, the patient has acute bronchitis, which is viral.
What to Offer Instead
Symptomatic Management Options
Provide symptomatic relief with 1:
- Cough suppressants: dextromethorphan or codeine
- Expectorants: guaifenesin
- First-generation antihistamines: diphenhydramine
- Decongestants: phenylephrine
Important caveat: β-agonists (albuterol) have not been shown to benefit patients without underlying asthma or COPD 1.
Patient Education and Expectations
Set realistic expectations:
- Acute bronchitis is self-limited, with cough lasting up to 6 weeks 1
- Symptomatic therapy does not shorten illness duration but may provide comfort 1
- Over-the-counter treatments have low incidence of minor adverse effects (nausea, vomiting, headache, drowsiness) 1
When to Reassess
Advise the patient to return or follow up if 2:
- Cough persists beyond expected timeframe
- Cough worsens or new symptoms develop
- Signs of pneumonia emerge (fever, tachycardia, tachypnea, abnormal lung exam)
At that point, consider targeted investigations and antibiotic therapy only if a complicating bacterial infection is thought likely 2.
The Telemedicine Context
This scenario is particularly high-risk for inappropriate prescribing. Research shows that 55% of pediatric respiratory infections received antibiotics during telemedicine visits, and prescribing antibiotics correlated with higher patient satisfaction ratings 3. However, prescribing antibiotics to meet patient expectations contributes to antimicrobial resistance and causes patient harm through adverse effects without clinical benefit 1, 4.
A 2002 randomized controlled trial directly comparing azithromycin to vitamin C for acute bronchitis found no difference in health-related quality of life or return to usual activities 4. The study was stopped early because azithromycin provided no benefit.
Common Pitfalls to Avoid
- Do not prescribe antibiotics because the patient requests them—patient satisfaction should not override evidence-based care
- Do not interpret purulent sputum as bacterial infection—this is a viral inflammatory response
- Do not order testing (chest X-ray, labs) unless pneumonia is suspected based on clinical criteria 1
- Do not prescribe "just in case"—this contributes to antibiotic resistance and exposes patients to unnecessary harm